ASTRO胃癌放疗临床实践指南
美国放射肿瘤学会(ASTRO)针对胃癌放疗的适应证、时机、剂量分割、靶区与技术制定循证推荐,覆盖可切除、不可切除、寡转移及姑息等临床情境,基于系统文献综述与预设共识方法学形成推荐。
要点
- 所有胃癌患者推荐多学科评估与决策。
- 可切除cT2-4和/或N+患者推荐围手术期化疗,优选FLOT方案。
- 不可切除或复发非转移患者可考虑根治性放化疗。
核心结论
- 该指南为胃癌放疗的临床应用提供循证推荐,指导适应证、时机、剂量分割、靶区与技术选择。
研究设计与样本
- ASTRO召集工作组,基于系统文献综述与预设共识方法学(含证据质量与推荐强度分级系统)制定推荐,回答3个关键问题。
主要发现
- 推荐所有患者进行多学科评估与决策。
- 对cT2-4和/或N+可切除胃癌,推荐围手术期化疗,优选FLOT(5-氟尿嘧啶、亚叶酸、奥沙利铂和多西他赛)。
- 围手术期度伐利尤单抗联合FLOT较单纯FLOT显著改善可切除患者无事件生存,现已成为标准治疗。
- 对不适合围手术期化疗者推荐术前放化疗;对切缘阳性(R1)或切除不完全(R2)有顾虑者条件性推荐术前放化疗。
- 对不适合围手术期或术后化疗者,或直接手术但切除欠佳(如<D2或R1-R2)者,条件性推荐术后放化疗。
关键数值与推荐
- 对初始诊断或局部区域复发时不可手术的非转移患者,根治性放化疗可能提供持久控制。
- 对寡转移性胃癌,条件性推荐转移灶定向治疗联合全身治疗。
- 姑息性放疗对出血、疼痛和梗阻有效。
- 指南提供了靶区覆盖目标和正常组织剂量指导。
临床怎么用
- 临床中应基于多学科评估,按可切除性、围手术期化疗适宜性、手术切除质量及转移状态选择放疗时机与方案。
- 可切除cT2-4和/或N+患者优先考虑围手术期FLOT化疗,不适合者考虑术前放化疗。
- 术后放化疗用于不适合围手术期或术后化疗者,或直接手术但切除欠佳者。
- 寡转移患者可考虑转移灶定向治疗联合全身治疗;出血、疼痛、梗阻可行姑息放疗。
局限性
- 未来研究将进一步细化放疗适应证及其在胃癌管理中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This guideline provides evidence-based recommendations addressing the indications for radiation therapy (RT) for gastric cancer in a variety of clinical settings, ranging from patients with resectable locoregional disease to metastatic and symptomatic disease. METHODS: The American Society for Radiation Oncology convened a task force to address 3 key questions: (1) indications for and timing of RT for patients with resectable and nonmetastatic gastric cancer; (2) indications for and timing of RT in patients with unresectable locoregional disease, oligometastases, and/or requiring palliation; and (3) appropriate RT dose-fractionation regimens, target volumes, and techniques in these clinical settings. Recommendations are based on a systematic literature review and were created using a predefined consensus-based methodology with a system for grading evidence quality and recommendation strength. RESULTS: Multidisciplinary evaluation and decision-making are recommended for all patients. For patients with cT2-4 and/or N+ resectable gastric cancer, perioperative chemotherapy is recommended, preferably FLOT (5-fluorouracil, leucovorin, oxaliplatin, and docetaxel). Recently, perioperative durvalumab and FLOT has shown a significant improvement in event-free survival versus FLOT only for patients with resectable disease and is now being adopted as a standard of care. Preoperative chemoradiation is recommended for patients who are not candidates for perioperative chemotherapy and conditionally recommended if there is concern for a margin-positive (R1) or incomplete (R2) resection. Postoperative chemoradiation is conditionally recommended for patients who are not candidates for perioperative or postoperative chemotherapy or if a suboptimal resection was done (eg, <D2 or R1-R2) for those who proceeded directly to surgery. Definitive chemoradiation may provide durable control for nonmetastatic patients who are inoperable either at initial diagnosis or at the time of locoregional recurrence. For patients with oligometastatic gastric cancer, metastasis-directed therapy along with systemic therapy is conditionally recommended. Palliative RT is efficacious for patients with bleeding, pain, and obstruction. Target coverage goals and dose guidance for normal tissues are provided. CONCLUSIONS: These evidence-based recommendations guide clinical practice on the use of RT for gastric cancer. Future studies will further refine the indications and role of RT in the management of these patients.
引用
- Anker CJ, Arshad J, Cellini F, et al. Radiation Therapy for Gastric Cancer: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol. 2025. PMID: 41317985. doi:10.1016/j.prro.2025.10.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。